Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis

Key clinical point: Denosumab raised spinal bone mineral density (BMD) significantly more than did oral alendronate.

Major finding: Lumbar spine BMD increased 3.5% with denosumab versus 2.5% with alendronate.

Study details: A 12-month study of 69 patients randomly assigned to denosumab and another 70 to alendronate.

Disclosures: The trial was an investigator-initiated study. Dr. Mok and colleagues had no relevant financial disclosures.


Mok CC et al. Arthritis Rheumatol. 2020;72(suppl 10). ACR 2020, Abstract 1442.